Overview

AMG 319 in HPV Positive and Negative HNSCC

Status:
Terminated

Trial end date:
2018-05-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether a drug called AMG 319 has an effect on a patient's own immune response to head and neck cancer squamous cell carcinoma (HNSCC). This study is specifically for patients who are having surgery to treat their HNSCC

Phase:

Phase 2

Details

Lead Sponsor:

Cancer Research UK

Treatments:

Adenosine
N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine